Skip to main content
Intrasense logo

Intrasense — Investor Relations & Filings

Ticker · ALINS ISIN · FR0011179886 LEI · 969500VF6MOVQXWHAE33 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2025-12-04 Report Publication Anno…
Country FR France
Listing PA ALINS

About Intrasense

https://www.intrasense.fr/

Intrasense, a subsidiary of the Guerbet Group, is a medical technology company that develops and markets advanced software solutions for medical imaging. Its flagship product, the Myrian® platform, is a comprehensive visualization tool that assists healthcare professionals in reviewing and analyzing 2D and 3D medical images from modalities such as MRI and CT scanners. The company's solutions are characterized by the native integration of Artificial Intelligence (AI) algorithms to enhance diagnostic accuracy and workflow efficiency. Intrasense also offers specialized solutions, including Liflow® for oncology imaging and the DUOnco™ suite of AI tools for lesion detection. The technology aims to facilitate and secure clinical diagnosis, decision-making, and therapeutic monitoring for radiologists and other clinicians.

Recent filings

Filing Released Lang Actions
Agenda financier 2026
Report Publication Announcement Classification · 100% confidence The document is a short press release titled 'Agenda financier 2026' (Financial Calendar 2026). It lists the expected dates for the publication of future financial results, annual reports, and the annual general meeting. It does not contain the actual financial reports themselves, but rather serves as an announcement of the reporting schedule. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-12-04 French
Intrasense : Rapport semestriel
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Rapport semestriel' (Interim Report) for the period ending June 30, 2025. It contains a management review, business updates, governance information, and a section titled 'Présentation des comptes' (Presentation of accounts). Although it is an interim report, it functions as a comprehensive financial and operational update for the first half of the fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-24 French
Intrasense : First half-year 2025 results
Earnings Release Classification · 95% confidence The document is a detailed press release titled 'First half-year 2025 results' for Intrasense. It contains a summary of financial performance, a simplified consolidated income statement, management commentary on the strategic roadmap, and future outlook. While it contains financial data, it is structured as a corporate press release announcing the results rather than a full statutory Interim Report (IR). According to the 'Menu vs Meal' rule, this is an announcement of the results, but since it provides the actual financial tables and detailed management discussion (MDA) within the release, it is best classified as an Earnings Release (ER) as it serves as the initial announcement of the period's financial results. H1 2025
2025-09-24 English
Intrasense : Résultats du premier semestre 2025
Earnings Release Classification · 98% confidence The document is a comprehensive report titled 'Résultats du premier semestre 2025' (First Half 2025 Results) for Intrasense. It contains detailed financial statements (consolidated income statement), management's discussion and analysis of business trends, strategic roadmap updates, and future outlook. While it is formatted as a press release, its length (6 pages) and the inclusion of detailed financial tables and operational analysis qualify it as an Interim/Quarterly Report (IR) rather than a simple announcement. H1 2025
2025-09-24 French
INTRASENSE : DUOnco™ Pancreas CE marking: a key innovation for the early detection of pancreactic cancer using AI
Regulatory Filings Classification · 95% confidence The document is a press release issued by Intrasense announcing the CE marking of their new medical device, 'DUOnco™ Pancreas'. It describes the product's function, its strategic importance, and provides contact information for investors and the press. As it is a general corporate announcement regarding a product milestone that does not fit into specific financial reporting categories like earnings, dividends, or governance, it is classified as a general regulatory filing/announcement.
2025-08-13 English
INTRASENSE : Certification CE de DUOnco™ Pancreas : une innovation clé pour la détection précoce du cancer du pancréas par IA
Regulatory Filings Classification · 100% confidence The document is a press release issued by Intrasense announcing the CE marking certification for their new medical software, DUOnco™ Pancreas. It details the product's clinical utility, its role in the company's strategy, and provides contact information for investors and the press. As it is a corporate announcement regarding a product milestone rather than a financial report, a regulatory filing, or a specific shareholder document, it falls under the general regulatory announcement category.
2025-08-13 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.